Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma

Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma

Background: Renal cell carcinoma is the third most prevalent urological cancer worldwide and about 30% of patients present with metastatic disease at the time of diagnosis. Systemic treatments for metastatic renal cell carcinoma have improved recently. Vascular endothelial growth factor targeting th...

Full description

Bibliographic Details
Main Authors: Emilien Billon, Jochen Walz, Serge Brunelle, Jeanne Thomassin, Naji Salem, Mathilde Guerin, Cecile Vicier, Slimane Dermeche, Laurence Albiges, Florence Tantot, Soazig Nenan, Geraldine Pignot, Gwenaëlle Gravis
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-10-01
Series:Frontiers in Oncology
Subjects:
renal cell carcinoma
nivolumab
immunotherapy
complete response
immune adverse events
vitiligo
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01033/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.01033/full

Similar Items